Serum PSA testing remains controversial as the data regarding its utility are conflicting. However, a recent study adds to the growing body of evidence supporting its usefulness in middle-aged men, especially in the determination of the long-term risk of metastasis and death from prostate cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
National Cancer Institute. Surveillance Epidemiology and End Results [online].
Nadler, R. B., Humphrey, P. A., Smith, D. S., Catalona, W. J. & Ratliff, T. L. Effect of Inflammation and Benign Prostatic Hyperplasia on Elevated Serum Prostate-Specific Antigen Levels. J. Urol. 154, 407–413 (1995).
Moyer, V. A. & US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann. Intern. Med. 157, 120–134 (2012).
Carter, H. B. et al. Early Detection of Prostate Cancer: AUA Guideline. J. Urol. doi:10.1016/j.juro.2013.04.119.
Vickers, A. J. et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40–55 and long term risk of metastasis: case-control study. BMJ 346, f2023 (2013).
Loeb, S., Carter, H. B., Catalona, W. J., Moul, J. W. & Schroder, F. H. Baseline prostate-specific antigen testing at a young age. Eur. Urol. 61, 1–7 (2012).
Ulmert, D. et al. Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study, BMC Med. 6, 6 (2008).
Vickers, A. J. et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ 341, c4521 (2010).
Grenabo Bergdahl, A., Holmberg, E., Moss, S. & Hugosson, J. Incidence of Prostate Cancer After Termination of Screening in a Population-based Randomised Screening Trial. Eur. Urol. doi:10.1016/j.eururo.2013.05.024.
Scosyrev, E., Messing, E., Mohile, S., Golijanin, D. & Wu, G. Prostate Cancer in the Elderly: Frequency of Advanced Disease at Presentation and Disease-Specific Mortality. J. Urol. 187, E137–E138 (2012).
Acknowledgements
We thank Stacy Loeb for reviewing this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
W. J. Catalona declares that he has received research support and honoraria for speaking and been an investigator for Beckman-Coulter, has received research support and royalties as co-inventor from and been an investigator and consultant for OHMX, has received research support from and been an investigator for deCODE genetics, and has been an investigator for Nanosphere. D. Reinhardt declares no competing interests.
Rights and permissions
About this article
Cite this article
Reinhardt, D., Catalona, W. The growing evidence supporting mid-life PSA testing. Nat Rev Urol 10, 436–438 (2013). https://doi.org/10.1038/nrurol.2013.144
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2013.144
